Novartis Investigative Site

Viña del Mar, Valparaiso 2540364

0 studies enrolling now · 9 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cancer, Cardiovascular Disease and Lipoprotein(a), Immune Thrombocytopenic Purpura (ITP), Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Neoplasms, Gastrointestinal Tract, Non Alcoholic Steatohepatitis (NASH), Polymyalgia Rheumatica, Renal Cell Carcinoma (RCC)

Studies at this site

• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. — Stopped early
• A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed